CY1124812T1 - Μεθοδος ανοσοενισχυτικης θεραπευτικης αντιμετωπισης του καρκινου - Google Patents

Μεθοδος ανοσοενισχυτικης θεραπευτικης αντιμετωπισης του καρκινου

Info

Publication number
CY1124812T1
CY1124812T1 CY20211101105T CY211101105T CY1124812T1 CY 1124812 T1 CY1124812 T1 CY 1124812T1 CY 20211101105 T CY20211101105 T CY 20211101105T CY 211101105 T CY211101105 T CY 211101105T CY 1124812 T1 CY1124812 T1 CY 1124812T1
Authority
CY
Cyprus
Prior art keywords
cancer
therapeutic treatment
immune boosting
boosting therapeutic
immune
Prior art date
Application number
CY20211101105T
Other languages
English (en)
Inventor
Sylvie Laquerre
Peter F. Lebowitz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50237545&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1124812(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1124812T1 publication Critical patent/CY1124812T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μια μέθοδο παροχής ανοσοενισχυτικής θεραπευτικής αντιμετώπισης σε άνθρωπο ασθενή, η οποία περιέχει τη χορήγηση στον εν λόγω ασθενή θεραπευτικώς αποτελεσματικών δόσεων δαμπραφενίμπης και τραμετινίμπης για χρονική περίοδο η οποία επαρκεί για την αύξηση της επιβίωσης άνευ υποτροπής [relapse-free survival (RFS)].
CY20211101105T 2012-09-04 2021-12-15 Μεθοδος ανοσοενισχυτικης θεραπευτικης αντιμετωπισης του καρκινου CY1124812T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261696375P 2012-09-04 2012-09-04
PCT/US2013/057432 WO2014039375A1 (en) 2012-09-04 2013-08-30 Method of adjuvant cancer treatment

Publications (1)

Publication Number Publication Date
CY1124812T1 true CY1124812T1 (el) 2022-11-25

Family

ID=50237545

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211101105T CY1124812T1 (el) 2012-09-04 2021-12-15 Μεθοδος ανοσοενισχυτικης θεραπευτικης αντιμετωπισης του καρκινου

Country Status (21)

Country Link
US (6) US20150216868A1 (el)
EP (2) EP3981408A1 (el)
JP (3) JP2015527374A (el)
KR (1) KR102134585B1 (el)
CN (2) CN104582706A (el)
AU (2) AU2013313050A1 (el)
BR (1) BR112015004578A2 (el)
CA (1) CA2882437C (el)
CY (1) CY1124812T1 (el)
DK (1) DK2892535T3 (el)
ES (1) ES2900825T3 (el)
HK (1) HK1206642A1 (el)
HR (1) HRP20211817T1 (el)
HU (1) HUE056646T2 (el)
IN (1) IN2015KN00449A (el)
LT (1) LT2892535T (el)
PL (1) PL2892535T3 (el)
PT (1) PT2892535T (el)
RU (1) RU2640180C2 (el)
SI (1) SI2892535T1 (el)
WO (1) WO2014039375A1 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3981408A1 (en) 2012-09-04 2022-04-13 Novartis AG Dabrafenib and trametinib in a method of adjuvant cancer treatment
CA2934822A1 (en) 2013-12-28 2015-07-02 Guardant Health, Inc. Methods and systems for detecting genetic variants
CA3057969A1 (en) * 2017-05-02 2018-11-08 Novartis Ag Combination therapy
US11890286B2 (en) * 2018-04-17 2024-02-06 The University Of Chicago Methods and compositions for treating cancer
CN109106893B (zh) * 2018-11-12 2021-04-20 上海市中西医结合医院 一种调节肠道屏障功能的中药复方制剂及其制备方法
WO2023105286A1 (en) 2021-12-06 2023-06-15 My Personal Therapeutics Ltd A combination treatment for cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52670B (en) 2004-06-11 2013-06-28 Japan Tobacco Inc. 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PIRIDO (2,3-D) PYRIMIDINE DERIVATIVES AND SIMILAR COMPOUNDS FOR CANCER TREATMENT
CA3054535A1 (en) * 2005-02-18 2006-08-24 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
HUE060206T2 (hu) * 2009-10-16 2023-02-28 Novartis Ag MEK gátlót és B-Raf gátlót tartalmazó kombináció
US20130004481A1 (en) * 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
EP3981408A1 (en) 2012-09-04 2022-04-13 Novartis AG Dabrafenib and trametinib in a method of adjuvant cancer treatment

Also Published As

Publication number Publication date
PL2892535T3 (pl) 2022-01-31
AU2013313050A1 (en) 2015-03-26
PT2892535T (pt) 2021-12-15
US20180338979A1 (en) 2018-11-29
HUE056646T2 (hu) 2022-02-28
US20200054641A1 (en) 2020-02-20
JP2015527374A (ja) 2015-09-17
SI2892535T1 (sl) 2022-01-31
CA2882437C (en) 2021-03-02
EP2892535A1 (en) 2015-07-15
EP3981408A1 (en) 2022-04-13
CA2882437A1 (en) 2014-03-13
ES2900825T3 (es) 2022-03-18
JP6511117B2 (ja) 2019-05-15
US20170202842A1 (en) 2017-07-20
EP2892535B1 (en) 2021-09-22
RU2640180C2 (ru) 2017-12-26
AU2016244279B2 (en) 2018-01-04
US20230330091A1 (en) 2023-10-19
JP6684941B2 (ja) 2020-04-22
JP2018058859A (ja) 2018-04-12
LT2892535T (lt) 2021-12-10
RU2015105821A (ru) 2016-10-20
IN2015KN00449A (el) 2015-07-17
US20150216868A1 (en) 2015-08-06
KR102134585B1 (ko) 2020-07-17
WO2014039375A1 (en) 2014-03-13
AU2016244279A1 (en) 2016-11-03
DK2892535T3 (da) 2022-01-03
CN107308164A (zh) 2017-11-03
BR112015004578A2 (pt) 2017-07-04
EP2892535A4 (en) 2016-04-13
KR20150047619A (ko) 2015-05-04
HK1206642A1 (en) 2016-01-15
CN104582706A (zh) 2015-04-29
JP2019142899A (ja) 2019-08-29
US10869869B2 (en) 2020-12-22
US20210060021A1 (en) 2021-03-04
HRP20211817T1 (hr) 2022-03-04

Similar Documents

Publication Publication Date Title
CY1124812T1 (el) Μεθοδος ανοσοενισχυτικης θεραπευτικης αντιμετωπισης του καρκινου
CY1120506T1 (el) Θεραπευτικα δραστικες ενωσεις και μεθοδοι χρησης αυτων
CY1123258T1 (el) Μεθοδος θεραπειας για τον καρκινο
CY1122466T1 (el) Σκευασμα αντισωματος αντι il-17ra και θεραπευτικα σχηματα για την αγωγη της ψωριασης
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
CY1122143T1 (el) Φαρμακευτικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της b-raf, εναν αναστολεα του egfr και προαιρετικα εναν αναστολεα της ρι3κ-αλφα
EA201790180A1 (ru) Способы и терапевтические комбинации для лечения опухолей
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
BR112015023910A2 (pt) terapia envolvendo anticorpos contra claudin 18.2 para tratamento de câncer
UA113403C2 (xx) Спосіб підвищення ефективності folr1 терапії раку
EA201590622A1 (ru) Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
NZ603319A (en) Diabetes therapy
EA201791736A1 (ru) Комбинированная терапия для лечения рака
EA201290603A1 (ru) Способ лечения
EA201390745A1 (ru) Активируемая пользователем автономная выполненная в едином корпусе система доставки лекарственного средства посредством ионофореза
ECSP17019893A (es) Tratamientos médicos a base de anamorelina
MX2021005878A (es) Modulador de empalme de herboxidieno de conjugados de anticuerpo-farmaco y metodos de uso.
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
MX369090B (es) Sultiame para el tratamiento de apnea del sueño.
TN2013000336A1 (en) 5s,8s)-3-(4'-chlor-3'-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for therapy.
BR112017027653A2 (pt) método para induzir a resposta de memória t precoce com vacina anti-tumoral de peptídeos curtos
EA201992762A1 (ru) Трансмукозальные устройства для доставки лекарств для применения при облегчении хронической боли
RU2014150506A (ru) Велипариб в комбинации с лучевой терапией всего мозга для лечения метастазов в головной мозг
EA201991206A1 (ru) Ремнантные опухоль-инфильтрирующие лимфоциты и способы их получения и применения